Treatment outcomes of vulvar and vaginal melanoma at an NCCN institution between 1993 and 2021
Survival was not significantly different by adjuvant therapy type or after 2011. Most patients who were disease-free five years after surgery had received adjuvant therapy. Seven patients experienced complete responses to therapy after recurrence of whom five received immune checkpoint inhibitors. Although survival is not improved as in cutaneous melanomas by immune checkpoint inhibitors, signal continues for the use of immune checkpoint inhibitors in gynecologic melanomas.
Authors
- Matthew Stephen Block (ORCID: https://orcid.org/0000-0001-5692-4219)
- Carrie Langstraat (ORCID: https://orcid.org/0000-0001-9361-8392)
- Luigi Antonio De Vitis (ORCID: https://orcid.org/0000-0003-3778-8666)
- Stuart A. Ostby (ORCID: https://orcid.org/0000-0002-3524-8626)
- Eleftheria Kalogera (ORCID: https://orcid.org/0009-0008-3614-5195)
- Michaela E. McGree
- Angela J. Fought (ORCID: https://orcid.org/0000-0002-7486-8596)
- S. Daniel
Institutions
- University of California, San Francisco (US)
- Mayo Clinic in Arizona (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- Gynecologic Oncology Reports
- Published
- 2024-08-13
- DOI
- https://doi.org/10.1016/j.gore.2024.101483
- Citations
- 2
- Primary Topic
- Cutaneous Melanoma Detection and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.57